Bronchogen is the synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Leu (AEDL). Its molecular weight is 446.45 Da, and its CAS number is not assigned.
Bronchogen, the synthetic tetrapeptide Ala-Glu-Asp-Leu (AEDL), is a short-chain cytogen studied as a tissue-specific bioregulator with pronounced affinity for cells of the bronchial epithelium and respiratory tract, including bronchial epithelial cells and alveolar structures. Its exceptionally small size (molecular weight 446.45 Da) enables it to readily cross cellular membranes, penetrate the nucleus without requiring receptor-mediated endocytosis or classical surface signaling pathways, and exert direct effects on nuclear components. Once inside the cell, AEDL localizes primarily to the nucleoplasm and nucleolus, where it modulates gene expression through direct interaction with DNA and chromatin structures rather than through conventional second-messenger systems.
The core molecular mechanism of Bronchogen involves sequence-specific binding to double-stranded DNA. Biophysical studies and molecular docking have identified a preferred binding motif for the AEDL tetrapeptide: the tetranucleotide CTCC sequence located in the promoter regions of genes associated with bronchial epithelial differentiation, mucin production, surfactant synthesis, and respiratory tissue homeostasis. Binding occurs preferentially in GC-rich regions and leads to local destabilization of the DNA double helix while simultaneously increasing DNA thermostability (melting temperature rises by approximately 3.1 °C). This interaction sterically hinders repressive chromatin complexes and may reduce inhibitory methylation activity, thereby maintaining promoters in a transcriptionally active, euchromatic state.
In addition to direct DNA interaction, Bronchogen modulates chromatin architecture by promoting deheterochromatinization. The tetrapeptide induces conformational changes that increase the proportion of transcriptionally active euchromatin while reducing condensed heterochromatin, particularly in aging bronchial epithelial cells. This epigenetic remodeling reactivates genes progressively downregulated during biological aging, significantly enhancing accessibility of transcription factors to target promoters without altering the underlying DNA sequence. This process represents a classic example of epigenetic regulation, allowing Bronchogen to influence youthful patterns of gene expression in senescent respiratory cellular systems.
Key target genes regulated by AEDL binding in their promoter regions include those involved in:
• Bronchial epithelial differentiation — NKX2-1 (Nkx2.1), SCGB1A1, SCGB3A2, FoxA1, and FoxA2 — associated with restoration of epithelial phenotype and secretory signaling activity;
• Mucin and surfactant production — MUC4, MUC5AC, and SFTPA1 — supporting protective mucus-layer formation and alveolar stability pathways;
• Proliferation and repair markers such as PCNA and Ki67 — supporting epithelial regeneration-associated signaling;
• Senescence and apoptosis regulators p16, p21, and p53 — whose expression is modulated under stress-associated conditions;
• Inflammatory and matrix-degrading pathways — whose activity is regulated to support balanced bronchial remodeling processes.
Furthermore, Bronchogen upregulates genes supporting ciliary function, barrier integrity, and anti-inflammatory signaling responses in bronchial and lung tissue models, promoting balanced tissue remodeling and cellular resilience.
Under conditions of oxidative, inflammatory, or age-related stress (such as chronic bronchitis-associated models, COPD-associated models, replicative senescence, or bronchial explant cultures), Bronchogen finely modulates proliferative and reparative signaling. It accelerates the transition of bronchial epithelial cells into active proliferative and differentiative phases while modulating excessive apoptosis and senescence-associated pathways. This temporal regulation supports restoration of respiratory tissue signaling competence and may reduce premature cellular aging pathways. Simultaneously, Bronchogen shifts intracellular balance toward survival-associated signaling, repair-associated pathways, and functional cellular maintenance.
Bronchogen demonstrates strong tissue specificity toward bronchial and respiratory tract cells, showing minimal activity in unrelated cell types due to the selective distribution of its DNA-binding motifs and chromatin partners in these tissues.
Biophysical studies suggest that Bronchogen may also interact with nuclear ribonucleoprotein complexes, stabilizing mRNA transcripts of the upregulated genes and improving translational efficiency. This multi-level regulation — encompassing direct DNA binding, chromatin deheterochromatinization, differentiation support, mucin and surfactant pathway modulation, and post-transcriptional stabilization — creates a comprehensive molecular program associated with bronchial homeostasis, epithelial integrity, and respiratory tissue resilience.
In experimental and research settings, Bronchogen is studied in relation to bronchial epithelial signaling, respiratory tissue homeostasis, chromatin remodeling, and cellular adaptation pathways associated with respiratory-system resilience.
Research models have explored associations with:
• bronchial epithelial proliferation and differentiation pathways;
• mucin and surfactant-associated signaling systems;
• ciliary activity and mucosal barrier integrity pathways;
• oxidative stress adaptation and inflammatory signaling regulation;
• respiratory tissue remodeling and epithelial renewal systems.
The peptide is frequently examined in experimental models involving chronic bronchitis-associated signaling environments, COPD-associated stress systems, replicative senescence, inflammatory respiratory models, and age-associated bronchial degeneration pathways.
Bronchogen also demonstrates anti-inflammatory and reparative signaling effects in respiratory-system experimental models. By modulating senescence-associated markers and inflammatory pathways while supporting reparative signaling programs, it is associated with balanced bronchial remodeling and epithelial adaptation under stress-associated conditions.
A consistently explored area of research involves respiratory-function-associated signaling and airway homeostasis pathways. In experimental bronchial and respiratory-system models, Bronchogen is associated with epithelial differentiation signaling, mucosal barrier support, airway remodeling regulation, and broader respiratory tissue resilience mechanisms.
Bronchogen is also studied in age-associated respiratory biological systems. Experimental findings suggest interactions with pathways related to bronchial elasticity, mucociliary signaling activity, epithelial renewal, and oxidative-stress-associated respiratory adaptation processes. These interactions are investigated within the broader context of respiratory aging biology and epithelial homeostasis.
Additional experimental observations include associations with respiratory recovery pathways following inflammatory or stress-associated respiratory conditions, along with modulation of mucosal barrier signaling systems. Studies in bronchial cell cultures and respiratory animal models confirm increased differentiation markers, elevated proliferation indices (PCNA), and reduced senescence- and apoptosis-associated signaling triggers (p53).
Bronchogen is characterized in experimental literature by strong tolerability and selective biological activity, with minimal adverse observations other than rare hypersensitivity-associated responses reported in research settings. These observed effects are associated with modulation of gene expression, chromatin remodeling, epithelial differentiation, mucin regulation, surfactant-associated pathways, and senescence-related signaling systems.
As a research peptide and short-chain bioregulator, Bronchogen continues to be explored in experimental models focused on respiratory epithelial biology, bronchial homeostasis, chromatin regulation, tissue adaptation pathways, and respiratory aging research.
Discover how respiratory bioregulator peptides are researched for bronchial epithelial support and lung-aging pathways.
→ What Are Bioregulator Peptides?
All information presented is based on experimental and preclinical research data and is intended for scientific and educational purposes only.
Este item é fornecido exclusivamente para fins de investigação.
Todas as informações fornecidas pela PRG destinam-se apenas a fins educativos e informativos.
Para manter a fiabilidade dos resultados laboratoriais, o armazenamento correto dos peptídeos é essencial. Condições adequadas ajudam a preservar a estabilidade dos peptídeos durante anos, protegendo-os contra contaminação, oxidação e degradação.
Embora alguns peptídeos sejam mais sensíveis do que outros, seguir estas boas práticas prolongará significativamente a vida útil e a integridade estrutural.
Os peptídeos podem ser comprometidos pela exposição à humidade e ao ar, especialmente após a remoção do congelador.
Os peptídeos em solução têm uma vida útil muito mais curta do que na forma liofilizada e são mais suscetíveis à degradação bacteriana.
Selecionar recipientes limpos, intactos, quimicamente resistentes e adequados ao volume da amostra.
Peptídeos enviados em frascos de plástico podem ser transferidos para vidro para armazenamento a longo prazo, se desejado.
